Table 1 Comparison between patients with or without hydroxocobalamin
Characteristics | All patients, N = 739 | Hydroxocobalamin, N = 386 | No hydroxocobalamin, N = 353 | p |
|---|---|---|---|---|
At admission | ||||
- Age in years | 50 (36–63) | 50 (38–62) | 48 (33–64) | 0.4858 |
- Sex female, n (%) | 271 (36.7) | 140 (36.3) | 131 (37.1) | 0.9335 |
- BMI in kg/m2 | 25 (22–28) | 24 (22–28) | 25 (22–28) | 0.2416 |
- Prehospital cardiac arrest (%) | 46 (6.2) | 42 (10.9) | 4 (1.1) | < 0.0001 |
- Prehospital GSC /15 | 15 (9–15) | 13 (5–15) | 15 (14–15) | < 0.0001 |
Comorbidities | ||||
- CKD, n (%) | 6 (0.8) | 6 (1.6) | 0 (0) | 0.0315 |
- CHT, n (%) | 141 (19.1) | 71 (18.4) | 70 (19.9) | 0.6872 |
- Diabetes mellitus, n (%) | 54 (7.3) | 33 (8.5) | 21 (6) | 0.2243 |
- Peripheral artery disease, n (%) | 22 (3) | 9 (2.3) | 13 (3.7) | 0.3882 |
- CHF, n (%) | 33 (4.5) | 20 (5.2) | 13 (3.7) | 0.4197 |
Burn characteristic | ||||
- Burn, n (%) | 577 (78.1) | 286 (74.1) | 291 (82.4) | 0.0081 |
- TBSA % | 20 (3–47) | 15 (0–45) | 24 (6–50) | 0.0163 |
- Deep burn TBSA % | 9 (0–30) | 5 (0–30) | 10 (0–32) | 0.1985 |
SOFA at admission | 4 (1–7) | 5 (2–8) | 2 (0–5) | < 0.0001 |
MAP in mmHg | 86 (72–101) | 86 (68–101) | 86 (73–101) | 0.4383 |
Vasopressors, n (%) | 226 (30.6) | 153 (39.6) | 73 (20.7) | < 0.0001 |
HbCO % | 3.6 (1.9–9.7) | 7 (3–15) | 3 (2–5) | < 0.0001 |
Biological data | ||||
- Plasma lactate in mmol/L | 3.0 (1.8–5.2) | 3.5 (2.1–6) | 2.6 (1.4–4.1) | < 0.0001 |
- Serum creatinine at admission in μmol/L | 76 (59–101) | 82 (63–106) | 71 (56–93) | 0.0031 |
- Maximal serum creatinine in μmol/L | 100 (73–162) | 108 (77–182) | 90 (71–137) | 0.0027 |
Inhalation fibroscopic status, n (%) | 305 (41.3) | 105 (27.5) | 200 (56.7) | < 0.0001 |
- Grade 0, n | 1 (0.1) | 0 (0) | 1 (0.3) | 1 |
- Grade 1, n | 121 (16.4) | 31 (8) | 90 (25.5) | < 0.0001 |
- Grade 2, n | 110 (14.9) | 37 (9.6) | 73 (20.7) | < 0.0001 |
- Grade 3, n | 73 (9.9) | 37 (9.6) | 36 (10.2) | 0.8764 |
During ICU hospitalization | ||||
- In-ICU mortality, n (%) | 243 (32.9) | 147 (38.1) | 96 (27.2) | 0.0022 |
- AKI in the first week, n (%) | 288 (39) | 166 (43) | 122 (34.6) | 0.0229 |
- Stage of AKI | ||||
- Stage 1, n (%) | 102 (13.8) | 52 (13.5) | 50 (14.2) | 0.8682 |
- Stage 2, n (%) | 39 (5.3) | 22 (5.7) | 17 (4.8) | 0.7099 |
- Stage 3, n (%) | 147 (19.9) | 92 (23.8) | 55 (15.6) | 0.0066 |
- Severe AKI, n (%) | 186 (25.2) | 114 (29.5) | 72 (20.4) | 0.0055 |
RRT at day 7, n (%) | 136 (18.8) | 86 (22.3) | 50 (14.2) | 0.006 |
- RRT in ICU, n (%) | 183 (24.8) | 107 (27.7) | 76 (21.5) | 0.0626 |
- MAKE, n (%) | 313 (42.4) | 187 (48.4) | 126 (35.7) | 0.0006 |
- Shock in ICU, n (%) | 402 (54.4) | 225 (58.3) | 176 (50) | 0.0261 |
- Length of stay in ICU in days | 15 (3–44) | 11 (2–36) | 22 (3–50) | 0.0161 |
- SAPS2 | 42 (27–60) | 49 (31–77) | 37 (23–54) | < 0.0001 |
- In-ICU survival, n (%) | 496 (67.1) | 239 (61.9) | 257 (72.8) | 0.0022 |
Nephrotoxic in ICU | ||||
- Aminoglycoside during hospitalization | 188 (25.4) | 81 (21) | 107 (30.3) | 0.0047 |
- Glycopeptide during hospitalization | 41 (5.5) | 16 (4.1) | 25 (7.1) | 0.1138 |
- Contrast agent | 74 (10) | 48 (12.4) | 26 (7.4) | 0.0299 |